| 1 |
NCT00796263 |
Recruiting |
Antiretroviral Therapy for Acute HIV Infection |
|
- Drug: HAART
- Drug: Mega-HAART
|
Interventional |
Phase 3 |
- South East Asia Research Collaboration with Hawaii
- Thai Red Cross AIDS Research Centre
- Pfizer
- (and 3 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- HIV-1 plasma viral RNA measurements and CD4 counts during follow-up and after therapy
- Number of HIV and non-HIV related clinical events
- Adverse events related to HAART
- (and 2 more...)
|
536 |
All |
18 Years and older (Adult, Senior) |
NCT00796263 |
HAART for Acute HIV infection |
AAHIV |
April 2009 |
April 2021 |
July 2021 |
November 24, 2008 |
April 19, 2018 |
|
- Thai Red Cross AIDS Research Centre
Bangkok, Thailand
|
| 2 |
NCT03149211 |
Not yet recruiting |
To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults |
|
- Drug: UB-421
- Drug: current standard HAART treatment
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants without virologic failure
- Time to virologic failure
- Number of participants with treatment-related adverse events
- (and 2 more...)
|
375 |
All |
20 Years and older (Adult, Senior) |
NCT03149211 |
UBP-A304-HIV |
|
September 2018 |
December 2021 |
December 2021 |
May 11, 2017 |
October 26, 2017 |
|
|
| 3 |
NCT00267865 |
Recruiting |
Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma |
- Lymphoma-AIDS-Related
- Brain Neoplasm
|
- Drug: Methotrexate
- Drug: Rituximab
- Drug: Leucovorin
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Survival; without recurrent lymphoma or severe cognitive problems at two years
|
28 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT00267865 |
060051
06-C-0051 |
|
December 16, 2005 |
July 31, 2019 |
July 31, 2021 |
December 21, 2005 |
April 4, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 4 |
NCT02563509 |
Recruiting |
Reconstitution of HIV-specific Immunity Against HIV |
|
- Biological: HIV-specific CD8 cells
|
Interventional |
Phase 1 |
- Guangzhou 8th People's Hospital
- Sun Yat-sen University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The number and function of HIV-specific CD8 cells in patients with HIV
- All adverse events
|
40 |
All |
16 Years to 60 Years (Child, Adult) |
NCT02563509 |
2013ZX10001004 |
|
January 2013 |
June 2017 |
December 2017 |
September 30, 2015 |
May 23, 2017 |
|
- Guangzhou 8th People's Hospital
Guangzhou, Guangdong, China
|
| 5 |
NCT03366922 |
Not yet recruiting |
Evaluation of Artemisia Annua and Moringa |
|
- Dietary Supplement: Artemisia Annua, Moringa oleifera
|
Interventional |
Not Applicable |
- Mbarara University of Science and Technology
- ANAMED
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
|
- CD4 counts
- Viral load
- Complete Blood Count
- (and 6 more...)
|
282 |
All |
18 Years and older (Adult, Senior) |
NCT03366922 |
27/05-17 |
|
December 10, 2017 |
December 10, 2019 |
December 10, 2019 |
December 8, 2017 |
December 8, 2017 |
|
|
| 6 |
NCT01697540 |
Recruiting |
Management of Highly Active Anti-retroviral Therapy-related Hyperlipidemia Among HIV-infected Patients in Taiwan |
|
|
Observational |
|
- Kaohsiung Medical University Chung-Ho Memorial Hospital
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
100 |
All |
Child, Adult, Senior |
NCT01697540 |
KMUHIRB-2012-05-05(I) |
|
September 2012 |
September 2019 |
|
October 2, 2012 |
April 28, 2017 |
|
- Tropical medicine center
Kaohsiung, Taiwan
|
| 7 |
NCT02945163 |
Recruiting |
Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy |
|
- Drug: Tenofovir
- Drug: Lamivudine
- Drug: Efavirenz
|
Interventional |
Phase 4 |
- Shanghai Public Health Clinical Center
- The Second Hospital of Nanjing
- Yunnan Provincial Infectious Disease Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of patients with HIV RNA<50 Copies/ml
- Adverse events
|
184 |
All |
18 Years to 60 Years (Adult) |
NCT02945163 |
2016-M-2 |
|
March 5, 2018 |
June 30, 2019 |
October 31, 2019 |
October 26, 2016 |
March 22, 2018 |
|
- The Second Hospital of Nanjing
Nanjing, Jiangsu, China - Shanghai Public Health Clinical Center
Shanghai, Shanghai, China - Yunnan provincial infectious disease hosipital
Kunming, Yunnan, China
|
| 8 |
NCT01428596 |
Recruiting |
Safety and Immunogenicity of HIVAX in HIV-1 Infected Subjects |
|
- Biological: HIVAX
- Biological: saline solution
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- • To evaluate the safety of a replication-defective HIV-1 vaccine (HIVAX™) in HIV-1 infected subjects on highly active antiretroviral therapy.
- • To evaluate the potential immunogenicity of a replication-defective HIV-1 vaccine (HIVAX™) as determined by IFN-γ and IL-2 ELISPOT to pooled gag and env HIV peptides.
- To explore the potential effectiveness of a replication-defective HIV-1 vaccine as a therapeutic vaccine
- To monitor the impact of antiretroviral treatment interruption on viral resistance among subjects with virologic rebound (HIV-1 RNA ≥5,000 copies/ml) following resumption of antiretroviral treatment.
|
30 |
All |
18 Years to 60 Years (Adult) |
NCT01428596 |
A010 |
GCHT01 |
September 2010 |
December 2017 |
December 2017 |
September 5, 2011 |
April 24, 2017 |
|
- University of Miami School of Medicine, AIDS Clinical Research unit
Miami, Florida, United States
|
| 9 |
NCT02276326 |
Recruiting |
Effects of VSL#3 on Neuro-cognitive Profile of HIV Patients |
|
- Dietary Supplement: VSL#3 sachets
|
Interventional |
Not Applicable |
- Azienda Policlinico Umberto I
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Delta of scores of questionnaires on quality of life
- Delta of scores of questionnaires on cognitive functions
- Delta of scores of questionnaires on behavioral functions
- Delta of value of serum lipopolysaccharide (LPS)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT02276326 |
VSL-Dett 2014 |
|
July 2014 |
December 2016 |
March 2018 |
October 28, 2014 |
December 5, 2016 |
|
- Policlinico Umberto I Hospital
Rome, Italy
|
| 10 |
NCT02415985 |
Recruiting |
Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly |
|
- Drug: Lopinavir/r will be supplied by NHSO/GPO
- Drug: Rifabutin
|
Interventional |
Phase 2 |
- The HIV Netherlands Australia Thailand Research Collaboration
- Bamrasnaradura Infectious Diseases Institute
- Chulalongkorn University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- pharmacokinetics of rifabutin Cmax
- adverse events
- viral load
- (and 12 more...)
|
40 |
All |
18 Years to 60 Years (Adult) |
NCT02415985 |
HIV-NAT 116 |
|
June 2015 |
September 2018 |
September 2018 |
April 14, 2015 |
August 10, 2017 |
|
- Chest Division, Faculty of Medicine, Chulalongkorn University
Bangkok, Thailand - HIV-NAT, Thai Red Cross - AIDS Research Centre
Bangkok, Thailand - Infectious Diseases, Faculty of Medicine, Chulalongkorn University
Bangkok, Thailand - Bamrasnaradura Infectious Diseases Institute
Nonthaburi, Thailand
|
| 11 |
NCT03037372 |
Not yet recruiting |
Statin Adjunct Therapy Among ART-treated Adults in Sub-Saharan Africa: Atorvastatin and Rosuvastatin Equivalence Trial |
|
- Drug: ART, Atorvastatin
- Drug: ART, Rosuvastatin
- Drug: ART, No statin
- Drug: Healthy-HIV-negative
|
Interventional |
Phase 3 |
- Makerere University
- University of Oxford
- Case Western Reserve University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Similar rate of reduction of immune activation between atorvastatin and rosuvastatin arms (p<o.05)
- Similar rate of change of immune aging markers, between ART-treated adults with and without statin (atorvastatin and rosuvastatin) adjunct therapy arms (P-value<0.05)
- Similar rate of reduction of inflammatory markers, between atorvastatin and rosuvastatin arms (p<0.05)
- Biological pathways affected by atorvastatin and rosuvastatin
|
320 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT03037372 |
DN2017 |
STAR |
June 1, 2017 |
June 30, 2022 |
December 31, 2022 |
January 31, 2017 |
January 31, 2017 |
|
|
| 12 |
NCT01161199 |
Recruiting |
The Use of Leukapheresis to Support HIV Pathogenesis Studies |
|
|
Observational |
|
- University of California, San Francisco
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT01161199 |
H52899-34904-01 |
|
July 2010 |
July 2020 |
July 2020 |
July 13, 2010 |
August 18, 2015 |
|
- San Francisco General Hospital
San Francisco, California, United States
|
| 13 |
NCT02431975 |
Recruiting |
Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial |
|
- Drug: Nevirapine
- Drug: Zidovudine
- Drug: Lamivudine
- Drug: LPV/r
|
Interventional |
Phase 4 |
- Columbia University
- National Institutes of Health (NIH)
- University of Witwatersrand, South Africa
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percent of patients with initial viral suppression
- Percent of patients maintaining viral suppression
- Prevalence of CD4 percentage greater than 30
- (and 3 more...)
|
60 |
All |
up to 48 Hours (Child) |
NCT02431975 |
AAAO5011
U01HD080441 |
LEOPARD |
August 2015 |
July 31, 2020 |
July 31, 2020 |
May 1, 2015 |
July 21, 2017 |
|
- Rahima Moosa Mother and Child Hospital
Johannesburg, Gauteng, South Africa
|
| 14 |
NCT00476606 |
Recruiting |
A Prospective Cohort of Children With HIV Infection |
|
- Drug: Zidovudine, Stavudine, Didanosine, Lamivudine
- Drug: Nevirapine, Efavirenz
- Drug: LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir
|
Observational |
|
- The HIV Netherlands Australia Thailand Research Collaboration
- Khon Kaen University
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- 1. To collect clinical and immunologic data of children treated with HAART 2. To collect clinical outcome data on children with HIV infection 3. To provide the best possible care to children with HIV infection
|
1000 |
All |
up to 20 Years (Child, Adult) |
NCT00476606 |
HIV-NAT 015 |
|
March 2003 |
December 2020 |
December 2020 |
May 22, 2007 |
February 24, 2017 |
|
- HIV-NAT
Bangkok, Thailand - Pediatric infectious diseases section, Chulalongkorn University
Bangkok, Thailand - Khon Kaen University
Khon Kaen, Thailand
|
| 15 |
NCT01137981 |
Recruiting |
Antiretroviral Pregnancy Registry (APR)-Risk of Birth Defects |
- Infection, Human Immunodeficiency Virus
|
- Drug: Any Antiretroviral Therapy
|
Observational |
|
- ViiV Healthcare
- GlaxoSmithKline
|
Industry |
- Observational Model: Other
- Time Perspective: Prospective
|
- A birth defect is defined as any congenital malformations according to modified (by APR) classification of Centers for Disease Control and Prevention (CDC)'s Metropolitan Atlanta Congenital Defects Program (MACDP) criteria
|
1 |
Female |
Child, Adult, Senior |
NCT01137981 |
112885
WE066 (EPIP095)
EPI40018 |
|
February 15, 1993 |
December 31, 2024 |
December 31, 2024 |
June 7, 2010 |
October 24, 2017 |
|
- GSK Investigational Site
Wilmington, North Carolina, United States
|
Create an RSS feed from your search for:
Download the search results for: